dapagliflozin and cardiovascular outcomes in type 2 diabetes - 2DM however there are few studies g4g1l diabetes for dapagliflozin as monotherapy The aim of this study was to assess the efficacy and safety of dapagliflozin as a monotherapy in T2DM and provide theoretical basis for clinical rational use of drugs Methods We did a systematic review and metaanalysis Prepare to become a physician build your knowledge lead a health care organization and advance your career with NEJM Group information and services NEW A digital journal for innovative original research and fresh bold ideas in clinical trial design and clinical decisionmaking Cardiovascular Risk Reduction in Type 2 Diabetes Therapeutic reduce the risk of further worsening of your kidney disease endstage kidney disease death due to cardiovascular disease and hospitalization for heart failure in adults with chronic kidney disease The DECLARE study Dapagliflozin will examine if dapagliflozin when added to current antidiabetic therapy is effective in reducing cardiovascular events compared with placebo Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes NEJM Conclusions Patients with type 2 diabetes mellitus and previous MI are at high risk of MACE and cardiovascular deathhospitalization for heart failure Dapagliflozin appears to robustly reduce the risk of both composite outcomes in these patients Type 2 Diabetes FARXIGA dapagliflozin Objective The aim of this study was to investigate the effect of dapagliflozin DAPA on the rate of heart failure rehospitalization in patients with acute myocardial infarction AMI and type 2 diabetes mellitus T2DM Methods AMI patients with T2DM from CZAMI registry between January 2017 This secondary analysis of a randomized clinical trial evaluates the relative safety and efficacy of dapagliflozin vs placebo by assessing risks of a composite of cardiovascular death and hospitalization for heart failure and of major adverse cardiovascular events according to baseline estimated Dapagliflozin in Myocardial Infarction without Diabetes or Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetesDiabetes Obes Metab 2019 21 812821 Dapagliflozin lowers plasma glucose concentration and improves βcell functionJ Clin Endocrinol Metab After 11 nearestneighbor propensity analysis with a followup of 150000 personyears Approximately 40 of the patients included in the study had type contoh poster diabetes 2 diabetes mellitus as their sole cardiovascular risk factor with no other risk factors Dapagliflozin and newonset type 2 diabetes in patients with chronic Likewise dapagliflozin reduced allcause mortality in patients with HFrEF HR 059 95 CI 040088 but not in those without HFrEF HR 097 95 CI 086110 P for interaction0016 In the first sodiumglucose cotransporter 2 inhibitor cardiovascular outcome trial to evaluate patients with type 2 diabetes Methods We randomly assigned patients outcome was a composite of major adverse cardiovascular events MACE defined as cardiovascular death myocardial infarction or ischemic stroke Dapagliflozin is a selective inhibitor glucosuria1113 Other SGLT2 inhibitors have shown favorable cardiovascular effects including a reduction in the risk of hospitalization for heart failure predominantly in patients with type 2 diabetes and established cardiovascular disease1416 DECLARETIMI 58 Wiki Journal Club Our results demonstrated that in the DECLARETIMI 58 trial Dapagliflozin Effect on Cardiovascular EventsThrombolysis in Myocardial Infarction 58 dapagliflozin appeared to reduce both major adverse cardiovascular events and cardiovascular death or heart failure hospitalization in patients Comparative cardiovascular outcomes in type 2 diabetes patients Dapagliflozin and Cardiovascular Outcomes in Patients With Type Its prevalence is expected to increase 30 years had T2DM in 2014 2 3 T2DM is strongly associated with an increased risk of cardiovascular diseases CVDs renal failure blindness and mortality 4 Thus the worldwide socioeconomic burden of T2DM is substanti Dapagliflozin is a selective inhibitor of sodium glucose cotransporter2 SGLT2 used in the control of type 2 diabetes The cardiovascular profile of dapagliflozin was previously not specified as it relates to safety In this randomized doubleblind multinational placebocontrolled phase DECLARETIMI 58 evaluated the effect of dapagliflozin on cardiovascular and renal outcomes in patients with type T2DM In the largest CVOT in diabetes conducted to date 17160 T2DM patients with a creatine clearance of at least 60 mLmin were randomized in a doubleblind manner to receive After 11 nearestneighbor propensity analysis with a followup of 150000 personyears Approximately 40 of the patients included in the study had type 2 diabetes mellitus as their sole cardiovascular risk factor with guidelines diabetes care 2019.pdf no other risk factors
type 2 diabetes causes nhs
effect of diet on type 2 diabetes mellitus a review
